Home>>ATG5 (human recombinant)

ATG5 (human recombinant)

Catalog No.GC40244

Autophagy-related 5 (ATG5), formerly known as apoptosis specific protein (ASP), is a protein that is essential to autophagosome elongation.

Products are for research use only. Not for human use. We do not sell to patients.

ATG5 (human recombinant) Chemical Structure

Size Price Stock
100μg
$677.00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Autophagy-related 5 (ATG5), formerly known as apoptosis specific protein (ASP), is a protein that is essential to autophagosome elongation. ATG5 is covalently conjugated to the C-terminal glycine residue of ATG12 (ATG12-ATG5) and forms a non-covalent complex with ATG16 (ATG12-ATG5-ATG16), which functions as an E3 ubiquitin ligase-like enzyme to facilitate LC3 transfer from ATG3 to phosphatidylethanolamine in canonical autophagy. ATG12-ATG5 also binds to the ATG12-ATG5-interaction region of the lysosomal localized protein TECPR1, freeing the TECPR1 pleckstrin homology domain to interact with phosphatidylinositol 3-phosphate components in the autophagosome membrane, promoting autophagosome-lysosome fusion. Polymorphisms in ATG5 have been associated with various autoimmune diseases, including lupus nephritis and Behcet's disease, gastrointestinal and colorectal cancers, as well as sporadic Parkinson's disease and childhood asthma.

Reviews

Review for ATG5 (human recombinant)

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ATG5 (human recombinant)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.